XVII International AIDS Conference Mexico City 3-8 July 2008

Conference Reports for NATAP


XVII International AIDS Conference Mexico City 3-8 August 2008

	Prevalence of Human Papillomavirus (HPV) Genotypes in HIV-1 Infected Women in Seattle, WA and Nairobi, Kenya - (10/06/08) - In Mexico City Viva Metabolics! - David Alain Wohl, MD - The University of North Carolina - (09/22/08) - ddI/FTC/ATV QD vs AZT/3TC bid+Efavrienz QD - Mark Mascolini - (08/28/08) - The Inflammatory Debate: Is it the Virus, the Drugs, or the Host? Reviewed by Charles Hicks, MD; Duke University Medical Center - (08/28/08) - Highly-sensitive C-reactive protein (hsCRP) is associated with body mass index (BMI) and serum lipids in HIV-infected patients with low cardiovascular disease (CVD) risk and virologic suppression on antiretroviral therapy (ART) - (08/28/08) - Clinicians Fail to Routinely Provide Reproductive Counseling to HIV-Infected Women in the United States - (08/27/08) - Societal Stigma of Pregnant HIV-Infected Women in the United States - (08/27/08) - IAS: Women's Rights Equals Women's Lives - from Mexico - (08/19/08) - IAS: HIV Crosses the Gender Divide - (08/19/08) - IAC Mexico City 2008 Summary Report - Written by Mark Wainberg - (08/26/08) - Efavirenz Stops HIV Better Than Lopinavir When Starting With Few CD4s - Mark Mascolini - (08/26/08) - IDX899, Novel HIV-1 NNRTI with High Barrier to Resistance, Provides Suppression of HIV Viral Load in Treatment-Naïve HIV-1-Infected Subjects - (08/26/08) - Efficacy and safety profile of APTIVUS oral solution or capsules co-administered with low dose ritonavir (APTIVUS/r) in treatment experienced children and teenagers after two years of treatment (Phase I/IIa study) - (08/25/08) - Impact of Baseline Antiretroviral Resistance Status on Efficacy Outcomes Among Patients Receiving Maraviroc Plus an Optimized Background Therapy (OBT) Versus Placebo Plus OBT in the MOTIVATE 1 and 2 Trials - (08/19/08) - Maraviroc Exposure-efficacy (<50 copies/mL) Analysis in HIV-1-infected Treatment-naive Subjects - ITT Population (MERIT Study) - (08/12/08) - CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Molecule CCR5 Antagonist - (08/12/08) - Maraviroc Exposure-safety Biomarker (Transaminases and Creatine Kinase) Analyses in MOTIVATE 1 and 2 Studies in HIV-1-infected Treatment-experienced Subjects - (08/12/08) - CD4+ Cell Restoration after 48 Weeks in the Maraviroc Treatment-experienced Trials MOTIVATE 1 and 2 - (08/12/08) - Efficacy, Safety and Tolerability of Etravirine With and Without Darunavir and/or Raltegravir in Treatment-Experienced Patients: Preliminary Analysis of TMC125-C214 Early Access Program (EAP) in the US - (08/13/08) - Response in Etravirine Expanded Access With Diverse Background Regimens - written by Mark Mascolini - - (08/07/08) The incidence of rash observed with the NNRTI etravirine in the Phase III DUET trials using pooled 48-week data - (08/07/08) Incidence and severity of nervous system and psychiatric events are similar with etravirine versus placebo: pooled 48-week data from the Phase III DUET studies - (08/07/08) Pharmacokinetics of etravirine are not affected by sex, age, race, treatment duration or use of enfuvirtide in HIV-1-infected subjects - (08/07/08) Combined darunavir and etravirine resistance analysis of the pooled DUET trials: when can we spare the other new classes? - (08/06/08) Responding to Darunavir/Etravirine For Patients With Resistance - written by Mark Mascolini - (08/11/08) Gender-Based Differences in ART-Naives in CASTLE Study: viral response, lipids, adverse events; and Other Gender-Based Studies at IAC - (08/19/08) - CD4+ T-cell Counts < 350 cells/mm3 Are a Risk Factor for Cardiovascular Disease in the HIV Outpatient Study (HOPS) - (08/19/08) - (NCEP)-based IDSA/ACTG Guidelines for Management of Cardiovascular Risk in the HIV Outpatient Study (HOPS) - (08/19/08) - At IAC Meeting on AIDS, Focus Shifts to Long Haul - (08/19/08) - Switching to Fosamprenavir (FPV) Led to Similar Efficacy and Safety in HIV-1-infected Subjects on their First PI Regimen: a Prospective, Open-label, Multicenter, Randomized Trial (ESS100290) - (08/18/08) - HLA-B*5701 Screening Reduces Abacavir Hypersensitivity Reactions (ABC HSR); Multiple Lines of Evidence to Establish a New Standard of Care - (08/18/08) - HIV-1 viral load in cerebrospinal fluid (CSF) of successfully treated patients on long-term HAART - (08/18/08) - Baseline evaluation in CSF and neuropsycho-logical testing in patients starting Monotherapy - (08/18/08) - Cognitive Disorders Despite Undetectable Viremia: Low Scores in The HIV Dementia Scale (HDS) - (08/18/08) - The Safety and Efficacy of Tenofovir DF (TDF) in Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-Naive Patients Through Seven Years - (08/15/08) - TMC278 long acting - a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers - (08/15/08) - Dose selection and pharmacokinetics-pharmacodynamics of darunavir coadministered with low-dose ritonavir in the DELPHI (TMC114-C212) trial in treatment-experienced, HIV-1-infected children and adolescents - (08/15/08) - HCV Increased Risk for MI and Stroke in HIV+, Study Reported at IAC - (08/13/08) - Renal Safety Profile of Tenofovir DF (TDF)-containing vs. Thymidine Analog-containing Regimens Through 144 Weeks in Antiretroviral-naive Patients - (08/13/08) - The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1-Infected Patients: A Four-Year Follow-up - (08/13/08) - Combination with Lamivudine (3TC) and Efavirenz (EFV) in Antiretroviral-Naive Patients Through Seven Years - (08/13/08) - Impact of Gender on Response to Lopinavir/ritonavir (LPV/r) Tablets Dosed QD or BID Administered with Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) in Antiretroviral-naive (ARV) Subjects: Results from Study M05-730 - (08/12/08) - Long-Term Impact of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, on Body Image Parameters in HIV-Infected Patients with Abdominal Fat Accumulation - (08/12/08) - Results from the 26-week Confirmatory, Phase 3 Trial of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, in HIV Patients with Excess Abdominal Fat: A Multicenter, Double-blind, Placebo-controlled Study with 404 Randomized Patients - (08/12/08) - Week-96 end of trial analysis of antiretroviral-naive patients randomized to the lopinavir/ritonavir single drug arm in the MONARK trial - (08/12/08) - ARTEMIS: lipid tolerability and safety of darunavir and lopinavir in antiretroviral-naive patients - (08/12/08) - Switching NRTI Backbone to Tenofovir Plus Emtricitabine (Truvada, TVD) Promptly Improves Triglycerides and LDL-cholesterol Levels in Dyslipidemic HIV-1 Infected Patients: The TOTEM Randomised Trial - (08/12/08) - Metabolic Outcomes from Prospective, Randomized Clinical Trials of Tenofovir DF (TDF) Compared to Thymidine Analog-containing Efavirenz-based Regimens in Antiretroviral-Naive Patients - (08/12/08) - Lopinavir/ritonavir (LPV/r) in Pregnancy: ART Pregnancy Registry - (08/12/08) - A Comparison of the Single Dose Bioavailability of a Ritonavir Tablet Formulation Relative to the Ritonavir Soft Gelatin Capsule in Healthy Adult Subjects - (08/12/08) - Lopinavir-ritonavir plus Nevirapine as a Strategy to Improve Nucleoside-Related Mitochondrial Toxicity in Chronically Treated HIV-Infected Patients: 48 Week Follow-Up of MULTINEKA Study - (08/12/08) - Clinical Predictors of Tenofovir-Associated Nephrotoxicity - written by Mark Mascolini - (08/11/08) Twelve-Study Analysis Implicates Certain PIs and NRTIs in Lipid Jumps - written by Mark Mascolini - (08/11/08) Cohort Studies Disagree on Tenofovir Role in Kidney Trouble - written by Mark Mascolini - (08/11/08) Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients: Results of a Large Retrospective Database Study - (08/20/08) - Coagulation factor levels are not affected by tipranavir (TPV/r) capsules or Vitamin E-containing solution formulations nor by comparator protease inhibitors (PI) - (08/20/08) - Heart Marker (hsCRP) Tied to Lipids and Weight in People With Tight HIV Control - written by Mark Mascolini - (08/11/08) Nevirapine Is Best Semen Penetrator in Study of Six PIs and Nonnucleosides - written by Mark Mascolini - (08/11/08) Similarity in Efficacy and Safety of Abacavir/Lamivudine (ABC/3TC) Compared to Tenofovir/Emtricitabine (TDF/FTC) in Combination with QD Lopinavir/Ritonavir (LPV/r) Over 96 Weeks in the HEAT Study - (08/11/08) - New Norvir Tablet Bioequivalence - (08/11/08) - NATAP Summary of IAC 2008 Clinical Late Breaker Abstracts - written by Andrew Zolopa, MD Stanford University - (08/11/08) - RAL-KAL: PHARMACOKINETICS OF COADMINISTERED RALTEGRAVIR AND LOPINAVIR-RITONAVIR IN HEALTHY ADULTS - (08/11/08) - High Rate of Bone Thinning in Healthy Gay Men Without HIV - written by Mark Mascolini - (08/08/08) HCV Emerging as New Sexually Transmitted Disease in MSM With HIV - written by Mark Mascolini - (08/08/08) Studies Disagree on Faster Failure With First-Line Abacavir/Lamivudine ACTG 5202 - (08/08/08) Abacavir and Heart Disease - written by Mark Mascolini - (08/08/08) Safety, Tolerability and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Women With HIV Infection: 24-Week Interim Analysis of GRACE (Gender, Race, And Clinical Experience) - (08/07/08) Study Suggests HIV Itself Unleashes Body-Fat-Change Cascade, Gene Study Suggests - written by Mark Mascolini - (08/07/08) Dangerous Liver Problem Seen After Switch to Raltegravir With Tipranavir - written by Mark Mascolini - (08/07/08) Efficacy and Safety By Racial Group in ARV-Naive Subjects Treated With Atazanavir/Ritonavir or Lopinavir/Ritonavir: 48-Week Results for the CASTLE Study - (08/07/08) TMC278 (rilpivirine), an investigational next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naive patients: 96-week results of study C204 - (08/06/08) Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines - (08/06/08) Raltegravir 96 Weeks data from Phase II Study in Treatment-Naive - (08/06/08) Compelling 96-Week Findings on Raltegravir as First-Line Option - written by Mark Mascolini - (08/06/08) Nonnucleoside TMC-278 Slated for First-Line Use Looks Good Through 96 Weeks - written by Mark Mascolini - (08/06/08) Lower CD4 Count Despite Undetectable Load Raises Risks of AIDS and Death - written by Mark Mascolini - (08/06/08) Switch to Atazanavir/Ritonavir Does Not Trim Trunk Fat in 48 Weeks - written by Mark Mascolini - (08/05/08) Resistance Test Before ART Erases Risk of Poor Viral Response - written by Mark Mascolini - (08/05/08) Mental Development Equivalent in ARV-Exposed and Unexposed Kids Without HIV - written by Mark Mascolini - (08/05/08) CDC underestimated new HIV cases by 40 percent - (08/02/08) Africa the worst hit by AIDS, by far - (08/02/08) PrEP for Prevention Has Arrived-Researchers Look to Daily Pill to Avert H.I.V. - (08/02/08) New Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel; Earlier HAART Recommended - (08/02/08) Africa the worst hit by AIDS, by far - (08/02/08) CDC Reports Higher Rates of New HIV Cases, Causes Controversy - (08/02/08) AIDS hitting Asian gays at high rates - UN - (08/02/08)